Published in Cancer Res on June 15, 1990
Dietary folate protects against the development of macroscopic colonic neoplasia in a dose responsive manner in rats. Gut (1996) 1.13
Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol (1995) 0.82
The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells. Br J Cancer (1995) 0.81
Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer. Br J Clin Pharmacol (1994) 0.78
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
Type 1 (insulin-dependent) diabetes and a highly variable locus close to the insulin gene on chromosome 11. Diabetologia (1985) 3.65
mTOR and cancer therapy. Oncogene (2006) 3.07
A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med (1993) 2.80
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
alpha-Amylase inhibitory activity of some Malaysian plants used to treat diabetes; with particular reference to Phyllanthus amarus. J Ethnopharmacol (2006) 2.38
Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ (1990) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors. Blood (1996) 2.11
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol (1995) 2.09
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation. J Biol Chem (1999) 2.08
Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol (2001) 2.03
Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer (2004) 1.92
Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res (1999) 1.89
Amplification of the gli gene in childhood sarcomas. Cancer Res (1989) 1.84
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst (1998) 1.82
Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res (1994) 1.75
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 1.60
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res (2001) 1.56
Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. Am J Pathol (1994) 1.55
Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol (1994) 1.48
Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res (1999) 1.47
Vincristine revisited. Crit Rev Oncol Hematol (1999) 1.46
Measurement of skin-to-kidney distance in children: implications for quantitative renography. J Nucl Med (1990) 1.44
Hereditary persistence of alpha-fetoprotein in a child with testicular germ cell tumor. Med Pediatr Oncol (1999) 1.43
Evidence for two discrete carbamyl phosphate pools in Neurospora. J Biol Chem (1971) 1.43
Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol (1995) 1.43
Monoclonal antibodies to the myogenic regulatory protein MyoD1: epitope mapping and diagnostic utility. Cancer Res (1992) 1.43
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol (1999) 1.41
Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol (1998) 1.41
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis. Med Pediatr Oncol (1994) 1.40
The influence of intracellular recovery and hypoxic cells on the radiation response of mammary tumours and skin in C3H mice. Br J Radiol (1969) 1.37
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res (2000) 1.35
Myogenic regulatory protein (MyoD1) expression in childhood solid tumors: diagnostic utility in rhabdomyosarcoma. Am J Pathol (1990) 1.34
Mutants affecting thymidine metabolism in Neurospora crassa. J Bacteriol (1969) 1.33
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Anti-inflammatory activities of the methanol extracts and an isolated furanoditerpene constituent of Sphenocentrum jollyanum Pierre (Menispermaceae). J Ethnopharmacol (2005) 1.29
Pyrimidine-specific carbamyl phosphate synthetase in Neurospora crassa. J Bacteriol (1970) 1.29
Mechanisms of resistance to rapamycins. Drug Resist Updat (2001) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res (2000) 1.27
p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res (2001) 1.26
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1997) 1.25
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol (1992) 1.24
P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol (2000) 1.22
Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. Cancer Res (1979) 1.21
Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest (1994) 1.19
Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer (2006) 1.17
Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res (1987) 1.17
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res (2000) 1.16
Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine (2004) 1.15
An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11. Cancer Gene Ther (2008) 1.15
Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol (1999) 1.14
An evaluation of the activity related to inflammation of four plants used in Thailand to treat arthritis. J Ethnopharmacol (2003) 1.14
Automated ligand fishing using human serum albumin-coated magnetic beads. Anal Chem (2007) 1.13
Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts. Br J Cancer (1977) 1.12
Measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with cancer. Pharmacotherapy (1993) 1.11
Tyrosinase inhibition by extracts and constituents of Sideroxylon inerme L. stem bark, used in South Africa for skin lightening. J Ethnopharmacol (2008) 1.11
Clinical studies with computer-assisted initial lidocaine therapy. Arch Intern Med (1984) 1.11
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res (1981) 1.09
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemother Pharmacol (1994) 1.08
P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther (1998) 1.08
The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin Oncol (1982) 1.07
Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr (1994) 1.07
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol (2001) 1.07
Ligand and protein fishing with heat shock protein 90 coated magnetic beads. Anal Chem (2008) 1.06
Allosteric and competitive displacement of drugs from human serum albumin by octanoic acid, as revealed by high-performance liquid affinity chromatography, on a human serum albumin-based stationary phase. J Chromatogr (1992) 1.06
Pharmacokinetics of fentanyl in neonates. Anesth Analg (1986) 1.05
Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood (1992) 1.05
Antimicrobial and antiinflammatory activities of extracts and constituents of Oroxylum indicum (L.) Vent. Phytomedicine (1998) 1.05
Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res (1999) 1.04
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res (1997) 1.04
Medicinal plants and Alzheimer's disease: from ethnobotany to phytotherapy. J Pharm Pharmacol (1999) 1.04
Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J Nat Prod (1999) 1.03
Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta (2000) 1.03
DNA polymorphisms in the apolipoprotein C-III and insulin genes and atherosclerosis. Atherosclerosis (1985) 1.03
Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer (2001) 1.03
Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol (1999) 1.02
Diabetic hypertriglyceridaemia and related 5' flanking polymorphism of the human insulin gene. Br Med J (Clin Res Ed) (1984) 1.02
Development and characterization of an immobilized human organic cation transporter based liquid chromatographic stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.02
{Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells. J Pharmacol Exp Ther (2010) 1.02
Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther (1994) 1.01
Immunohistochemistry of MyoD1 in adult pleomorphic soft tissue sarcomas. Am J Surg Pathol (1995) 1.01
Ethnopharmacology of some Buddleja species. J Ethnopharmacol (1984) 1.01
Copurification of pyrimidine-specific carbamyl phosphate synthetase and aspartate transcarbamylase of Neurospora crassa. Biochemistry (1970) 1.01
Herceptin. Handb Exp Pharmacol (2008) 1.01
Light-Induced Trans to Cis Conversion of beta-d-Glucosyl o-Hydroxycinnamic Acid in Melilotus alba Leaves. Plant Physiol (1964) 1.00
The effects of target specification on objects fixated during visual search. Acta Psychol (Amst) (1967) 1.00
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother Pharmacol (1998) 1.00
Effect of acute phase response on phenytoin metabolism in neurotrauma patients. J Clin Pharmacol (1997) 1.00